Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak - SSA - Service de santé des armées Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2022

Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak

Rhéa Khoury
  • Fonction : Auteur

Résumé

The ongoing monkeypox virus (MPXV) outbreak is the largest ever recorded outside of Africa. Genomic analysis revealed a divergent phylogenetic lineage within clade 3, and atypical clinical presentations have been noted. We report the sequencing and isolation of the virus from the first clinical case diagnosed in France in May 2022. We tested the in vitro effect of tecovirimat (ST-246), a FDA approved drug, against this novel strain, showing efficacy at the nanomolar range. In comparison, cidofovir showed activity at micromolar concentrations. These results and the safety profile of tecovirimat strongly support its use in clinical care of severe forms for the 2022 MPXV outbreak.

Domaines

Virologie
Fichier principal
Vignette du fichier
2022.07.19.500484v2.full.pdf (595.02 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification

Dates et versions

pasteur-04036302 , version 1 (19-03-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Gaëlle Frenois-Veyrat, Franck Gallardo, Olivier Gorgé, Elie Marcheteau, Olivier Ferraris, et al.. Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak. 2022. ⟨pasteur-04036302⟩

Collections

PASTEUR SSA ANR
26 Consultations
14 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More